A Double-Blind, Randomized, Placebo-Controlled, Two-Dose Comparative Study of Botulinum Toxin Type A for Treating Glabellar Lines in Japanese Subjects
Systematic, well-controlled clinical trials of botulinum toxin type A (BoNTA) in diverse patient populations are needed. The aim of this study was to characterize the safety and efficacy of 10-U and 20-U BoNTA doses versus placebo for treating glabellar lines in Japanese subjects.
A 16-week, multicenter, double-blind, randomized, placebo-controlled trial comparing 10 or 20 U of BoNTA versus placebo in 142 Japanese subjects with glabellar lines of at least moderate severity at maximal contraction. The primary efficacy endpoint was physician-rated line severity at maximal contraction 4 weeks after treatment. Secondary efficacy endpoints included physician/subject ratings and estimates of the effect’s duration.
Response rates by physician-rated line severity at maximal contraction (week 4) were 86.4% (10 U), 88.6% (20 U), and 0% (placebo, p < 0.001). Line severity at maximal contraction in each BoNTA group (p < 0.001) improved significantly from baseline at each visit. BoNTA and placebo differed significantly on all other efficacy measures. Mean duration of effect was 9.4 weeks in the 20-U group and 7.9 weeks in the 10-U BoNTA group. No serious adverse events occurred.
Doses of BoNTA of 10 and 20 U are effective and safe for treating glabellar lines in Japanese subjects, and the 20-U dose provides greater efficacy and longer duration of effect.
- Carruthers A, Carruthers J, Lowe NJ, Menter A, Gibson J, Nordquist M, Mordaunt J, for the BOTOX® Glabellar Lines I & II Study Groups (2004) One-year, randomised, multicenter, two-period study of the safety and efficacy of repeated treatments with botulinum toxin type A in patients with glabellar lines. J Clin Res 7:1–20
- Carruthers J, Fagien S, Matarasso SL, the Botox Consensus Group (2004) Consensus recommendations on the use of botulinum toxin type A in facial aesthetics. Plast Reconstr Surg 114(Suppl 6):1S–22S CrossRef
- Carruthers JA, Lowe NJ, Menter MA, Gibson J, Nordquist M, Mordaunt J, Walker P, Eadie N, for the BOTOX Glabellar Lines I Study Group (2002) A multicenter, double-blind, randomized, placebo-controlled study of the efficacy and safety of botulinum toxin type A in the treatment of glabellar lines. J Am Acad Dermatol 46:840–849 CrossRef
- Carruthers JD, Lowe NJ, Menter MA, Gibson J, Eadie N, for the Botox Glabellar Lines II Study Group (2003) Double-blind, placebo-controlled study of the safety and efficacy of botulinum toxin type A for patients with glabellar lines. Plast Reconstr Surg 112:1089–1098 CrossRef
- Carruthers A, Carruthers J (2007) Patient-reported outcomes with botulinum neurotoxin type A. J Cosmet Laser Ther 9(Suppl 1):32–37 CrossRef
- Carruthers J, Carruthers A (2007) Botulinum toxin type A treatment of multiple upper facial sites: patient-reported outcomes. Dermatol Surg 33:S10–S17 CrossRef
- Fagien S, Cox SE, Finn JC, Werschler WP, Kowalski JW (2007) Patient-reported outcomes with botulinum toxin type A treatment of glabellar rhytids: a double-blind, randomized, placebo-controlled study. Dermatol Surg 33:S2–S9 CrossRef
- Stotland MA, Kowalski JW, Ray BB (2007) Patient-reported benefit and satisfaction with botulinum toxin type A treatment of moderate to severe glabellar rhytides: results from a prospective open-label study. Plast Reconstr Surg 120:1386–1393 CrossRef
- Carruthers A, Carruthers J, Said S (2005) Dose-ranging study of botulinum toxin type A in the treatment of glabellar rhytids in females. Dermatol Surg 31:414–422
- Carruthers JDA, Carruthers JA (1992) Treatment of glabellar frown lines with C. botulinum-A exotoxin. J Dermatol Surg Oncol 18:17–21
- Gordon MF, Barron R (2006) Effectiveness of repeated treatment with botulinum toxin type A across different conditions. South Med J 99:853–861 CrossRef
- Carruthers A, Carruthers J (2005) Prospective, double-blind, randomized, parallel-group, dose-ranging study of botulinum toxin type A in men with glabellar rhytids. Dermatol Surg 31:1297–1303
- Allergan, Inc. (2005) Botox Cosmetic package insert. Irvine, CA: Allergan, Inc.
- De Boulle KLV (2007) Botulinum neurotoxin type A in facial aesthetics. Expert Opin Pharmacother 8:1059–1072 CrossRef
- A Double-Blind, Randomized, Placebo-Controlled, Two-Dose Comparative Study of Botulinum Toxin Type A for Treating Glabellar Lines in Japanese Subjects
- Open Access
- Available under Open Access This content is freely available online to anyone, anywhere at any time.
Aesthetic Plastic Surgery
Volume 32, Issue 5 , pp 724-730
- Cover Date
- Print ISSN
- Online ISSN
- Additional Links
- Botulinum toxin
- Japanese subjects
- Glabellar lines
- Industry Sectors
- Author Affiliations
- 1. Department of Plastic and Reconstructive Surgery, School of Medicine, Kyorin University, 6-20-2, Shinkawa, Mitaka-shi, Tokyo, 181-8611, Japan
- 2. Department of Dermatology, School of Medicine, Tokyo Women’s Medical University, 8-1, Kawada-cho, Shinjuku-ku, Tokyo, 162-8666, Japan